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CHAPTER 1  
1. LITERATURE REVIEW 
1.1 Introduction 
Osteoporosis is a systemic skeletal disease characterised by low bone mass and 
microarchitectural deterioration of bone tissue, with subsequent increased bone 
fragility and vulnerability to fracture (1). Fragility or low trauma fractures are fractures 
that result from minimal trauma, such as a fall from a standing height or less. 
Typical sites for fragility fracture are the vertebrae, hip and distal forearm; though other 
sites, including the upper arm, pelvis, ribs and clavicle may be involved (2). 
1.2 Physiology of Bone 
The skeleton has locomotive and structural functions, and it serves as a reservoir of 
calcium and phosphate essential for homeostasis maintenance (3). It consists of 80 
percent cortical bone and a minimum of 20 percent trabecular bone (4). Skeletal sites 
determine cortical to trabecular bone ratios. The vertebra is made of a 25:75 ratio of 
cortical to trabecular bone. The ratio in the femoral head is 50:50 and in the radial 
diaphysis is 95:5 (5). 
Bone turnover is a lifelong process carried out by osteoclasts and osteoblasts.  It 
incorporates growth, modelling and remodelling to repair microdamage and access to 
the mineral reservoir (3).  
Bone remodelling is coordinated to preserve a balance between the amount of bone 
formed and the amount resorbed.  Basic multicellular units (BMUs) carry out bone 
remodelling and consist of osteoblasts, osteoclasts, cells in the bone lining and 
osteocytes (4). The remodelling cycle comprises three sequential phases: resorption, 
during which osteoclasts digest old bone; reversal, when mononuclear cells emerge 
on the bone surface; and formation when osteoblasts lay down new bone to replace 
the resorbed bone completely (5). 
Bone resorption: Osteoclast formation, differentiation and activation are regulated by 
the ratio of RANKL to osteoprotegerin, IL-1 and IL-6, colony-stimulating factor (CSF), 
PTH, 1,25-dihydroxy vitamin D, and calcitonin (6), (7). The osteoclasts in the resorbing 
compartment secrete hydrogen ions using cell membrane H+-ATPase pumps and 
chloride channels to reduce the pH to as low as 4.5, thus helping to mobilise bone 
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mineral (8). Resorbing osteoclasts secrete tartrate-resistant phosphatase acid, 
cathepsin K, matrix metalloproteinase 9, and cytoplasmic lysosomal gelatinase to 
digest the organic matrix (9).  
Osteoblasts express RANKL that binds its receptor, RANK, on the osteoclasts surface 
and their precursors. RANK activation stimulates differentiation, activation and survival 
of osteoclasts (10). Osteoprotegerin, a glycoprotein secreted by osteoblasts, inhibits 
bone resorption by binding to RANKL and preventing it from attaching to its receptor, 
RANK (11). 
Bone formation: Osteoblasts arise from mesenchymal stem cells in the stroma of the 
bone marrow and are responsible for the synthesis and subsequent mineralisation of 
bone matrix (12). Bone morphogenetic proteins (BMPs), TGF-β, PTH, and WNTs are 
amongst the cytokines involved in osteoblast differentiation (13). Runx2 / Cbfa1 (14) 
and Osterix/ Sp7 (15) are crucial regulators of bone formation involved both in 
endochondral and intramembrane ossification. Upon recruitment into to the 
reabsorbed area, osteoblasts produce the new, initially uncalcified (osteoid) bone 
matrix and then promote (facilitate) its mineralisation, thus (thereby) completing the 
cycle of bone remodelling (16).  
The Wnt/β-catenin signalling pathway plays an important role in the osteoblasts 
differentiation and proliferation (17). Activation of Wnt/β-catenin signalling occurs by 
binding of Wnt to the low-density lipoprotein receptor protein 5/6 (LRP5/6) and the 
Frizzled co-receptor. The receptor complex prevents the phosphorylation and 
degradation of β-catenin resulting in cytoplasmic accumulation and subsequent 
nuclear translocation of β-catenin (18). Upon translocation into the nucleus, β-catenin 
regulates osteoblasts gene transcription (19). 
Sclerostin, a glycoprotein produced by osteocytes, inhibits bone formation by exerting 
antagonistic effect on Wnt/β-catenin signalling pathway. It acts by binding LRP5/6, 
displacing the Wnt proteins, and leading to dissociation of the LRP5/6 and Frizzled 
receptor complexes (20). 
Peak bone mass, defined as the most substantial amount of bone that an individual 
can achieve, is an essential determinant of risk for an osteoporotic fracture (21). The 
age at which PBM is reached varies by sex and skeletal site; Lumbar spine PBM 
occurs at ages 33 to 40 years in females and 19 to 33 years in males, while total hip 
PBM occurs at ages 16 to 19 years in females and 19 to 21 years in males (22). 




include genetics, vitamin D, calcium, protein, sex steroids, IGF-1, physical activity and 
body weight (23). 
1.3 Diagnosis of osteoporosis 
The WHO describes osteoporosis as a bone mineral density (BMD) measured by Dual 
Energy X-ray Absorptiometry (DEXA scan) at hip or spine of 2.5 standard deviations 
(SD) or more below the mean for a young adult woman. Other categories as per WHO 
classification include (24), (25):  
- Normal: T-score at -1.0 SD and above.  
- Osteopaenia: T-score between – 1.0 and < 2.5 SD. 
- Severe osteoporosis: T-score at or below −2.5 with one or more fractures. 
In clinical practice, osteoporosis can also be diagnosed with the presence of a fragility 
fracture in postmenopausal women or men over the age of 50 with or without BMD 
measurement (26).  
Despite BMD measurement remains the most useful tool for diagnosis of osteoporosis 
and determining fracture risk, it has some limitations. These limitations include: 
- Technical factors can affect BMD measurements made by DEXA scan. Falsely 
elevated BMD is commonly caused by vertebral disease, such as osteoarthritic 
spondylosis, osteophytes, scoliosis, or vertebral fracture, as well as extrinsic artefacts 
from calcifications and surgical metalwork. Incorrect positioning can also affect BMD 
accuracy (27).  
- A single BMD measurement has a high specificity (±85%) for predicting fracture risk, 
but it lacks sensitivity, with less than half of patients with a known osteoporotic fracture 
having a BMD value in the osteoporotic range (i.e. T-score ≤ -2.5) (28).  
- A low BMD can also be caused by metabolic bone diseases other than osteoporosis 
(e.g. osteomalacia), which are treated differently than osteoporosis (28).  
- DEXA scans produce two-dimensional images of complex three-dimensional 
structures, and BMD is calculated as the ratio of bone mineral content to bone area. 
An obvious flaw of this method is that a larger bone may appear to have greater 
strength, but it may actually have the same BMD as a smaller bone (29). 






1.4 Epidemiology of Osteoporosis 
As the life expectancy is getting longer and society is getting older, the number of new 
cases of osteoporosis is anticipated to increase significantly worldwide.  
Osteoporotic fractures are expected to rise in both men and women by more than 
three-fold over the next 50 years (31). Annually, osteoporosis causes more than 8.9 
million fractures worldwide, and an osteoporotic fracture occurring every three  
seconds (32). 
 
Osteoporosis in sub-Saharan Africa 
 
Sub-Saharan Africa's population is aging more rapidly than any other region in the 
world, with projections of 161 million people over 60 by 2050 (33). This aging process 
with rapid urbanisation are shifting disease burdens across the region, resulting in a 
higher prevalence of noncommunicable diseases such as osteoporosis (34).  
Studies on osteoporosis in sub-Saharan Africa, including South Africa, are scarce and 
challenged by many factors including paucity of data and limited resources which need 
to be allocated to more epidemic diseases such as HIV and tuberculosis (TB). The 
lack of publications of osteoporosis research in sub-Saharan Africa was demonstrated 
in a recent study published in January 2020 (A call to action for osteoporosis research 
in sub-Saharan Africa) (35).  
In Kenya, Sitati et al (2020) reported a prevalence of osteoporosis of 26.4% in a cross-
sectional survey of 254 postmenopausal women, with a positive correlation with age, 
poverty, illiteracy, and underweight (36).  
In a 5-year retrospective study conducted in Tanzania in 222 patients who sustained 
a hip fracture, 75.6% of these fractures were fragility fractures. Over 5 years, the 
authors observed a 2.34% increase in fragility fractures per year in all included hip 
fractures (37). 
Unlike Afro-Americans, who have significantly higher BMD than their white 
counterparts, local studies in South Africa have revealed that vertebral BMD in blacks 
and whites is the same, and vertebral fracture rates appear to be comparable in the 
black and white populations. Hip BMD values in blacks, on the other hand, are 
significantly higher (38). 
The incidence of hip fractures in black South Africans is the lowest globally, as 
represented by the study done by Paruk et al. (39). This lower incidence might be 




their white peers, as reported by Conradie et al. (40). Matsela et al. 2017 in a small 
cohort of 68 black South African women, showed that 11.1% of premenopausal 
women had osteopenia while 34.4% and 25% of postmenopausal women had 
osteopenia and osteoporosis, respectively (41). 
1.5 Risk factors for osteoporosis and fracture 
There are modifiable and non-modifiable risk factors for osteoporosis and fracture 
(Table I).  
Assessment of fracture risk due to osteoporosis was vastly improved in 2008 by the 
introduction of the FRAX tool by the WHO Collaborating Centre at the University of 
Sheffield (42). FRAX estimates the 10 year probability of hip fracture and other major 
osteoporotic fracture (spine, distal forearm, and proximal humerus) by using clinical 
risk factors, either alone, or in combination with femoral neck BMD (42). These factors 
include age between 40 and 90 years, female gender, previous osteoporotic fracture, 
parental history of hip fracture, current smoking, excess alcohol intake (3 or more 
units/day), glucocorticoids use (7.5 mg or more for 3 months or longer at present or in 
the past), rheumatoid arthritis, and other secondary causes of osteoporosis (42).  
 
1.6 Screening for Osteoporosis 
The US National Osteoporosis Foundation (NOF) recommends BMD testing for 
women ≥ 65 years old and men ≥ 70 years old. For postmenopausal women and men 
between the ages of  50 – 69 years, NOF recommends BMD testing based on a risk 
factor profile (26). The US Preventive Services Task Force (USPTEF) recommends 
screening with the same NOF criteria for women but doesn’t recommend any 
screening in men (43). The National Osteoporosis Foundation of South Africa 
(NOSFA) supports a risk factor-based, case-finding strategy, as opposed to population 







1. Modifiable Risk Factors (44–49)
Smoking  
Excess alcohol consumption 
Physical inactivity  
Low BMI  
Reduced intake of calcium,  
vitamin D deficiency  
Frequent falls  
2. Non-modifiable Risk Factors (50–54)
Advanced age   
Female sex  
White ethnicity  
Personal history of fracture 
Parental history of fracture  
3. Secondary causes (55–66)
Rheumatoid arthritis  
Gastrointestinal diseases (e.g. post-gastrectomy state, inflammatory bowel 
disease (IBD), and celiac disease),  
Chronic liver disease  
Chronic renal failure  
COPD  
Endocrine disorders (e.g. Cushing’s syndrome, thyrotoxicosis, primary 
hyperparathyroidism, diabetes, primary or secondary hypogonadism)  
Haematological malignancies  
HIV  
Use of certain drugs (e.g. long term use of glucocorticoids, levothyroxine, 
anticonvulsants, aromatase inhibitor, heparin, PPI, SSRI). 
1.7 Treatment of Osteoporosis 
Treatment of osteoporosis is recommended for postmenopausal women and men over 
the age of 50 years with a hip or vertebral fracture, a T score of ≤ –2.5, or a combination 





1. Women ≥ 65 years, and men > 70 years. 
2. Known causes of secondary osteoporosis: 
• Early menopause (< 45 years of age), prolonged (longer than one year) oligo- or 
amenorrhoea in premenopausal women, or other causes of hypogonadism in 
women or men. 
• Systemic diseases known to adversely affect bone (Table I).  
• Bone-toxic drugs (Table I). 
3. Radiographic evidence of vertebral fracture or apparent osteopenia. 
4. History of fragility fracture after age 40 years. 
5. Presence of strong clinical risk factors: 
• Family history of hip fracture or osteoporosis. 
• Excessive leanness (BMI < 19 kg/m2). 
• Regular alcohol intake (more than two drinks per day). 
• Smoking. 
• Poor nutrition/calcium intake/Vitamin D exposure. 
6. To facilitate decisions regarding drug initiation or discontinuation (e.g. hormone 
therapy, bisphosphonates). 
 
of osteopenia (T-score between –1 and –2.5) and a FRAX score showing a 10-year 
probability of a hip fracture of ≥ 3% or a major osteoporotic fracture of ≥ 20% (28), 
(67). 
1.7.1 Lifestyle measures 
 
Increasing the level of physical activity and regular weight-bearing exercise, smoking 
cessation, decreasing alcohol consumption to ≤2 units per day, reducing the risk of 
falls and ensuring adequate dietary calcium intake and vitamin D status are the most 
effective lifestyle measures to improve bone health (68). 
Small increases in BMD have been shown by increasing calcium intake, either through 
the diet or in the form of supplements (69). A calcium intake of 1,000 to 1200 mg per 
day should be ensured if possible through dietary intake. This dose is shown in a 
recent meta-analysis to significantly reduce the risk of any fracture by 6% and a hip 
fracture by 16% (70).  If it is not possible, as is the case in South Africa (food 





fortification is rare and ample exposure to ultraviolet light is often difficult to achieve), 
supplementation may be required (28).  
Vitamin D when combined with calcium supplementation results in a small reduction 
in hip and nonvertebral fractures, and possibly also in vertebral fractures (71). A 
greater effect is noted in individuals with low dietary calcium intake than in those 
whose dietary intake is high (71). For postmenopausal women and men ≥ 50 years 
who are at an increased risk of fracture, a daily dosage of 800 IU cholecalciferol is 
recommended (68). A dose of ≥800 of vitamin D may also reduce the risk of falls 
(72). 
 
1.7.2 Pharmacological treatment 
 
Prior to commencing pharmacotherapy, patients should be assessed for secondary 
causes of osteoporosis and have their BMD measured by DEXA, when available, and 
vertebral imaging studies when appropriate.  
Pharmacologic agents used for the treatment and prevention of osteoporosis are 
classified into two main categories: 1. Antiresorptives (i.e., inhibiting osteoclast-
mediated bone resorption) 2. Anabolics (i.e., stimulating osteoblasts to form new 
bone). 
 




Bisphosphonates are  the most widely used pharmacological agents for the prevention 
and treatment of osteoporosis (73). They strongly bind to calcium crystals and inhibit 
osteoclastic bone resorption by causing apoptosis of osteoclasts or interfering with 
specific intracellular pathways in those cells (74).  
Bisphosphonates registered for the treatment of osteoporosis in South Africa include 
oral alendronate (daily and weekly), oral risedronate (weekly and monthly), 
ibandronate which is available as a three-monthly IV injection and monthly oral tablets, 




Several randomised placebo-controlled clinical trials have shown that 
bisphosphonates decrease fracture risk in postmenopausal women and men with 
osteoporosis (75).   
Zoledronic acid is the most potent bisphosphonate available. It is given as 5 mg once-
yearly intravenous infusion over a period of at least 15 - 30 minutes (76). It is more 
convenient and an alternative option for patients who cannot tolerate oral 
bisphosphonates or who have adherence issue. 
The HORIZON Pivotal Fracture Trial showed that once-yearly infusion of zoledronic 
acid over three year period compared to placebo decreased the risk of hip fracture, 
nonvertebral fractures, any clinical fractures, and clinical vertebral fractures by 41% 
(P=0.002), 25% (P<0.001), 33%(P<0.001), and 77% (P<0.001), respectively, over a 
3-year period. There was also significant increment in BMD at the total hip (6.02%), 
lumbar spine (6.71%) and femoral neck (5.06%) with zoledronic acid as compared to 
placebo (P<0.001 for all comparisons) (77). 
A meta-analysis of 8 randomised controlled trials including a total of 13,335 patients 
showed zoledronic acid, compared with placebo, significantly reduced the incidences 
of nonvertebral fractures (p=0.00), vertebral fractures (p=0.00), and hip fractures 
(p=0.02) (78). The same meta-analysis revealed significant increment of BMD from 
baseline at all measured sites (lumbar spine [p=0.00], total hip [p=0.00], femoral neck 
[p=0.00], and trochanter [p=0.02]) when zoledronic therapy compared to placebo. 
Bisphosphonates generally have a good safety profile, but upper gastrointestinal (GI) 
adverse effects (reflux, esophagitis, oesophageal ulcers) are relatively common with 
oral preparations, particularly when the patient reclines within 30- 60 minutes after 
taking the drug (79). A flu-like syndrome characterised by low-grade fever, myalgias, 
and arthralgias, may occur 24 to 72 hours after an intravenous (IV) bisphosphonate 
infusion (80). ONJ and AFF are rare but serious adverse events that may occur with 
the use of bisphosphonates. ONJ has been more commonly reported in cancer 
patients on higher cumulative doses of bisphosphonates than osteoporotic patients 
treated with lower doses and AFF with prolonged use of bisphosphonates (median 
treatment seven years) (81).  
After five years of oral bisphosphonate or three years of intravenous bisphosphonate, 
NOFSA suggests considering drug holiday in patients who are not at high risk for 
fracture (28). In patients with high risk (e.g., older women, a low hip T-score or high 
fracture risk score, previous major osteoporotic fracture, or those who fracture on 
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therapy), continuation of treatment for up to ten years (oral) or six years (intravenous), 
with periodic evaluation, should be considered (81). 
There remain uncertainties about the optimum treatment regimen, namely the effective 
lowest dose and/or longest dosing interval (82).  In a randomized control trial, 180 
postmenopausal women were randomized to receive single baseline doses of 
placebo, or 1 mg, 2.5 mg, or 5 mg zoledronic acid, to investigate the effects of doses 
of zoledronic acid lower than 5 mg. Every zoledronic acid dose resulted in similar 
increases in bone density and decreases in bone turnover markers after a year (83). 
While the effects of the 1 mg dose had been offset/reversed after two years, the 2.5 
mg dose showed effects comparable to the 5 mg dose (84).  In study by Bolland et al 
(2012), increases in BMD and decreases in bone turnover markers were maintained 
for at least 5 years after zoledronic acid administration in 43 HIV-infected men 
randomized to two annual doses of placebo or 4 mg intravenous zoledronic acid (85). 
1.7.2.1.2 Oestrogen 
Estrogen alone or combined with progestin (in women with an intact uterus) used to 
be one of the common treatments for postmenopausal osteoporosis (86). Its main 
action is to inhibit osteoclastic bone resorption. A network meta-analysis assessing 
the efficacy of estrogen with or without progestin in postmenopausal women with 
osteoporosis revealed a reduction in the risk of vertebral, hip and nonvertebral 
fractures of 34%, 29%, and 21%, respectively (87).  Three years of estrogen therapy 
increases spine BMD by 3.5% to 5% and hip BMD by 1.7%, as shown in the 
Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (88). Due to significant 
side effects (increased risk of breast cancer, VTE, and CAD) demonstrated by the WHI 
study, estrogen therapy is now less favourable (89).  
1.7.2.1.3 Selective Oestrogen Receptor Modulators (SERMS) 
SERMS act as estrogen agonists in bone, reducing bone loss by suppressing bone 
resorption. Tamoxifen and raloxifene have antagonistic estrogen action on breast, 
however only; tamoxifen has an agonistic estrogen effect on the uterus 
and is associated with an increased risk of endometrial cancer with long-term use 




in postmenopausal women. In the study conducted by Delmas et al. 1997, raloxifene 
had a significant increase in BMD in the lumbar spine (2.5%), femoral neck (2%), 
and full-body (1.9%) (91). 
The Multiple Outcomes of Raloxifene Evaluation (MORE) trial showed that treatment 
with raloxifene 60 or 120 mg/day for three years decreased the risk of vertebral fracture 




Calcitonin acts by binding osteoclast receptors inhibiting bone resorption. The Salmon 
calcitonin, is more potent than human calcitonin and is the most widely used. The FDA 
has approved both nasal and subcutaneous calcitonin for the treatment of 
postmenopausal osteoporosis. The PROOF study showed that nasal calcitonin at a 
dose of 200 IU/day decreased vertebral fractures by 33% (93). Endocrine Society 
guidelines suggest nasal spray calcitonin in postmenopausal osteoporosis who cannot 
tolerate other antiresorptive and/or anabolic medications.  
Calcitonin nasal spray has also been found to be beneficial in decreasing the pain 
associated with osteoporosis-related vertebral compression fractures and can be used 
with standard analgesics (94). NOFSA considers the use of calcitonin in the treatment 
of symptomatic vertebral fracture syndrome not cost-effective and does not 
recommend it. Salmon calcitonin is often associated with side effects such as nausea, 
vomiting, and flushing; these side effects are far less frequent with the nasal route 
(95). Rhinitis and epistaxis may occur with the use of calcitonin nasal spray (96). 
Although a causal relation between cancer and calcitonin use has been postulated 
before, a meta-analysis published in Osteoporosis International found that the 
relationship is weak and causality is unlikely (97).  
 
 
1.7.2.1.5 Strontium Ranelate 
 
The precise mechanism of action of strontium ranelate is not well understood. One 
study revealed dual effects for strontium ranelate; stimulating osteoblastic bone 
formation and inhibiting osteoclastic bone resorption (98). In a 3-year randomised 




41% and increased BMD in lumbar spine and femoral neck by 14.4% and 8.3%, 
respectively (99). It was approved by European Medicines Agency (EMA) in 2004 for 
treatment of osteoporosis in postmenopausal women. An increased risk of myocardial 
infarction, venous thromboembolism, and heart failure has been associated with 
strontium use. The available trial data indicate that the risk of cardiovascular events 
and VTE outweigh any benefit of strontium in fracture prevention (100). Due to the 
reported increased risk of cardiac events, EMA published new recommendations for 
strontium ranelate use in February 2014 (101). These new recommendations include:  
- Strontium Ranelate should only be used in men and postmenopausal women with 
severe osteoporosis when other medications are contraindicated or not tolerated. 
- Strontium Ranelate use must be avoided in patients with a history of IHD, peripheral 
arterial disease, and/or cerebrovascular disease or in patients with uncontrolled 
hypertension. 
NOFSA recommends strontium ranelate as second-line therapy for patients who 
cannot be treated with other osteoporosis approved medications. Strontium ranelate 




Denosumab is a human monoclonal antibody that binds RANKL and reduces bone 
resorption by inhibiting osteoclast formation, function and survival (102). The Fracture 
Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) 
trial showed that denosumab increased spine BMD by 9.2% and hip BMD by 4.0% 
(103). A post hoc analysis of the FREEDOM trial and its extension demonstrated an 
increased risk of multiple vertebral fractures, especially in those with a prior history of 
vertebral fractures, on cessation of denosumab (104). Therefore, in patients who stop 
denosumab for any reason, another antiresorptive agent like a bisphosphonate should 
be initiated without delay.  
It is recommended as a 60 mg dose sc every 6 months for men and postmenopausal 
women with osteoporosis who are at high risk for fracture failed or are not tolerating 
bisphosphonates, or have advanced renal impairment (105). ONJ and atypical femur 
fracture are uncommon (106).  
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1.7.2.2 Anabolic agents 
1.7.2.2.1 Teriparatide and abaloparatide 
Teriparatide [PTH (1–34)] and abaloparatide (PTH-related protein analogue) are 
anabolic peptides that increase bone formation and bone mineral density when given 
intermittently (107). They are recommended for treating osteoporosis in 
postmenopausal women at high risk for fracture (women with a history of osteoporotic 
fractures or have multiple risks for fracture) or those who fail or are intolerant to other 
agents (108). The FDA  has also approved teriparatide for osteoporotic men at high 
risk of fracture (109).  
Based on reported cases of osteosarcoma in rats treated with high doses of PTH (1-
34) (110), both teriparatide and abaloparatide are given for only up to 2 years and
antiresorptive agents should be commenced thereafter to preserve bone density (108). 
A meta-analysis has reported that teriparatide decreases the risk of vertebral fractures 
by 74 % and the risk of nonvertebral fractures by 39% in postmenopausal women 
(87). In the same meta-analysis reported, a reduction of 87% in the risk of vertebral 
fractures and a reduction of 46% in the risk of nonvertebral fractures using 
abaloparatide. 
Side effects of teriparatide include dizziness and leg cramps (111), whereas side-
effects of abaloparatide include nausea, postural hypotension, dizziness, headache, 
and palpitations (112). Botha agents can cause mild hypercalcemia (112).  
1.7.2.2.2 Romosozumab 
Romosozumab is a monoclonal antibody against sclerostin. Binding of romosozumab 
to sclerostin inhibits its activity and enhances osteoblastic bone formation and bone 
mineral density increment. (113) The FDA approved romosozumab in April 2019 for 
postmenopausal women with a history of a fragility fracture or multiple risk factors for 
a fracture, or those who do not tolerate or fail other osteoporotic therapies. It has not 
been approved yet for the treatment of osteoporosis in men. 
In the FRAME trial, a monthly injection of romosozumab for 12 months reduced the 
risk of a vertebral fracture by 73% and continued to show a substantial reduction in 
vertebral fracture (75%) at 2 years after the transition to denosumab (114). The ARCH 
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study found that 1 year of romosozumab followed by alendronate compared to 2 years 
of alendronate resulted in a reduction in the risk of vertebral fractures (by 48%), hip 
fractures (by 38%), and nonvertebral fractures (by 19%) at 24 months 
(115).  Romosozumab is only recommended for one year, and an antiresorptive agent 
should be started thereafter to maintain bone density. Side effects of romosozumab 
include an increased frequency of injection site reactions, and CV events (CAD and 
CVA) (115). Patients with a prior history or at increased risk of MI or stroke should not 
receive romosozumab. 
1.7.3 Monitoring of therapy 
Guidelines recommend using a DEXA scan to monitor BMD in patients who are being 
treated for osteoporosis.  The Endocrine Society suggests monitoring BMD by DEXA 
at the spine and hip every 1 to 3 years to assess the response to treatment (108). The 
frequency of BMD measurements may be decreased if the BMD appears to reach a 
plateau (109). Although the evidence for using BMD to monitor treatment response is 
weak, it does suggest that it can be used for this purpose (116). 
Bone turnover markers are an alternative method suggested for monitoring of therapy. 
The cost, limited availability of DEXA and the delay in detecting changes in BMD after 
initiation of treatment support the function of bone turnover markers (BTMs) as short-
term therapy monitoring tools (117). They include markers of bone formation and bone 
resorption.  
Markers of bone formation are active osteoblast products expressed at various stages 
of their development and are considered to represent various aspects of osteoblast 
function and bone formation. They include by-products of collagen synthesis 
(propeptides of type 1 collagen [C-terminal: P1CP, N-terminal: P1NP]), osteoblast 
enzymes (total and bone-specific ALP), and matrix proteins (osteocalcin). 
Markers of bone resorption are products formed during the bone resorption phase of 
bone remodelling. They include collagen degradation products (telopeptides of type 1 
collagen [C‑terminal: CTX‑1, N‑terminal: NTX‑1], hydroxyproline, and pyridinium 
crosslinks [pyridinoline, deoxypyridinoline]), noncollagenous proteins (bone 
sialoprotein), osteoclastic enzymes (Tartrate‑resistant acid phosphatase, Cathepsin 




Serum P1NP (as a reference of bone formation) and serum CTX-1 (as a reference of 
bone resorption) have been suggested by the International Osteoporosis Foundation 
(IOF) and International Federation of Clinical Chemistry and Laboratory Medicine to 
be used for assessment of monitoring of treatment (119).  
In-patient variability, biological variability (age, gender, BMI, food intake, circadian and 
menstrual variation); and poor standardisation of most assays are some of the 
limitations that need to be considered when using BTMs for monitoring treatment 
(120). 
 
1.7.4 Treatment failure 
 
By consensus, the  IOF established criteria to define treatment failure in patients 
adherent to therapy (121). These criteria include: 
 two or more incident fragility fractures 
 one incident fracture with a substantial decrease in bone density 
 one incident fragility fracture that occurs with the lack of suppression of bone-
remodelling markers 
 persistently elevated bone formation (example, PINP) and bone resorption 
markers (example, βCTX-I) with a significant decrease in bone density.  
A substantial decrease in bone density is when it exceeds 5% in the lumbar spine and 
4% in the proximal femur.  When monitoring bone turnover markers, a 25% change 
(decrease for anti-resorptive agents and an increase for anabolic agents) in levels from 
baseline is considered an adequate response (121).  
Predictors of treatment failure include higher FRAX score, ≥2 falls in the past year, 
previous fracture, current use of glucocorticoids, arms more frequently required to help 
in standing, and unexplained weight loss ≥4.5 kg (122). 
There is no evidence available on the efficacy of alternative treatments when one has 
been considered to have failed treatment. Three general rules are recommended, 
based on the opinion of IOF working group (121): 
(1) A more potent anti-resorptive medication fairly replaces a weaker one of the same 
class.  
(2) An injectable drug reasonably substitutes an oral drug.  
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Clinical characteristics, complications and treatment outcomes of patients 
with osteoporosis at Groote Schuur Hospital 
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Background: Osteoporosis has become a major problem worldwide as the population 
ages. An osteoporotic fracture is associated with a high rate of morbidity and mortality. 
Data on the prevalence, risk factors and outcome of osteoporotic fractures in South 
Africa remains sparse.   
Method: A retrospective audit was undertaken in all patients attending the Endocrine 
Clinic at Groote Schuur Hospital between March 2019 and March 2020 for the 
treatment of osteoporosis. Patients folders were reviewed to obtain the following 
information: demographic data, risk factors, laboratory investigations, treatment, 
baseline and follow up DEXA scans.  
Results: 264 patients were evaluated, average age 65.7 ± 12.3 years, 92.8% (n=245) 
were female. Common risk factors included smoking (50.8%, n=134), vitamin D 
deficiency (29.2%, n=77), steroid use (21.6%, n=57) and primary hyperparathyroidism 
(15.2%, n=40).  A fragility fracture was diagnosed in 68.6% (n=181) - vertebral only 
(54.7%, n=99), hip only (14.9%, n=27), vertebral and hip (10.5%, n=19), wrist (7.2%, 
n=13) and other (12.7%, n=23).  Bisphosphonates were used by 75% (n=198) of 
patients at the time of enrolment. Of these, 80.8% (n=160) received intravenous 
zoledonic acid alone, 6.1% (n=12) received oral alendronate alone and 13.1% (n=26) 
initially received alendronate followed by intravenous zoledronic acid. Over 5.4 years 
there was an improvement in bone mineral density (BMD) of 4.4% at the lumbar spine, 
while there was slight worsening of BMD at the left femoral neck (- 0.5%).  A fracture 






Conclusion: The majority of patients with osteoporosis at Groote Schuur Hospital had 
a fragility fracture at diagnosis with a vertebral fracture being most common. 
Bisphosphonate treatment showed a measurable improvement in BMD at the lumbar 
spine. However, there was no improvement at the femoral neck. Despite this, few 
patients had symptomatic vertebral or hip fracture whilst on treatment.   
 
Keywords: Osteoporosis, South Africa, BMD, fragility, fracture, bisphosphonates, 
zoledronic acid, alendronate  
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2.2 Aims and Objectives 
The aim of this study was to conduct an audit of all patients with osteoporosis managed 
at the Endocrine Clinic at Groote Schuur Hospital between March 2019 and March 
2020. These findings will contribute to the development of a cost-effective strategy for 
the management of patients with osteoporosis at Groote Schuur Hospital.     
Objective 1: To describe the patient characteristics, risk factors and causes for 
osteoporosis.  
Objective 2:  To maintain an active database of patients with osteoporosis seen at the 
Endocrine Clinic at Groote Schuur Hospital.  
Objective 3: To describe the prevalence, phenotype, clinical presentation and risk 
factors for patients presenting with a fracture.  
Objective 4: To determine the effectiveness of the various treatment modalities used 
to reduce fracture risk. 
Objective 5: To determine the outcome of using intravenous zoledronic acid 
2.3 Methods 
2.3.1 Study design 
Retrospective Cross-sectional Study 
2.3.2 Setting 
Endocrine Clinic at Groote Schuur Hospital (GSH), a tertiary hospital in Cape Town, 
South Africa. 
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2.3.3 Study population 
All patients attending the Endocrine Clinic at Groote Schuur Hospital between March 
2019 and March 2020 who have a diagnosis of osteoporosis.  These patients were 
referred with either a fragility fracture or low BMD.  
2.3.4 Procedures 
Folder reviews were done to retrieve the following information: 
1. Demographic details: age, sex
2. Past history: fractures, co-morbidities, previous medications and supplements.
3. Risk factors: vitamin d deficiency, primary hyperparathyroidism, CKD,
diabetes, inflammatory bowel disease, hyperthyroidism, HIV, hypogonadism,
smoking, and alcohol.
4. Family history: osteoporosis, fractures
5. Clinical details: weight, height, and BMI.
6. Treatment: type of medication, doses, response to treatment, fractures whilst
on treatment. Was patients with current steroid use included?
How many women received HRT?
7. Laboratory results: vitamin D level, calcium, phosphate, PTH, serum protein
electrophoresis, creatinine, ALT, AST, GGT, ALP, sex steroids.
8. DEXA scan result at diagnosis and latest.
2.3.5 Data safety, analysis and monitoring 
All patient data were de-identified, and study participants were given a unique study 
number. Data and analysis records are kept in a password-protected database on a 
secure computer. The password was unique and known only to the investigators. This 
was in keeping with the Declaration of Helsinki 2013. 




2.3.6 Statistical analysis 
 
Descriptive statistics were used to summarise demographic characteristics, known 
risk factors, fracture history, changes in bone mineral density, medical management 
received, and fracture while on treatment. The primary outcomes of interest were 
response to treatment, changes in bone mineral density, and fracture while on 
treatment. Depending on the distribution of the data, mean with standard deviation 
(SD) or median with interquartile range (IQR) were used to summarise continuous 
variables. Frequencies with percentages were used to summarise categorical data.  
The Wilcoxon rank-sum or the Kruskal-Wallis test were used to compare continuous 
variables between groups. Where continuous variables were not normally distributed 
between two groups, they were compared using ANOVA, and binary and categorical 
variables were compared using Pearson's chi-squared test. Data analysis were 
performed using Stata/SE version 16.1 (StataCorp®, College Station, Texas). 
 
2.3.7 Ethical aspects  
 
Ethics approval was obtained from the UCT - Faculty of Health Sciences Human 
Research Ethics Committee (UCTHREC ref 169/2019) (Ethics approval for the study 
– see Appendix 2). Since it is a retrospective study, no individual patient consent was 
required. 
2.4 Results 
A retrospective folder review was done on all patients attending the Endocrine Clinic 
at GSH from 15 March 2019 to 15 March 2020 for management of osteoporosis. The 
12-month period for the study was selected in order to capture most of the patients 
with osteoporosis attending the Endocrine Clinic as the majority of these patients come 
for follow up at least every 6 to 12 months. Over the study period, 271 patients were 
included, 7 were excluded on the basis of incomplete data or wrong diagnosis (4 had 
no DEXA scan, 1 had osteomalacia, 2 had osteopenia). Therefore, 264 patients were 
included in the final analysis.  The majority of these patients [68.6% (n =181)] were 






Baseline characteristics and risk factors 
 
The baseline characteristics and pre-existing risk factors are shown in Table 1. Of the 
264 patients enrolled in the study, females represented the majority of the cohort 
(n=245, 92.8%). The mean age at diagnosis was 65.7 ±12.3 years, with males 
presenting at a younger age (60.1 ± 15.9 years) compared with females (66.2 ± 11.9 
years).  The average BMI of all the patients was 26.7 ± 5.5 kg/m2, with males having 
a slightly higher BMI (27.1 ± 6.9 kg/m2) than females (26.6 ± 5.4 kg/m2). 
In the females, the mean age of menarche was 13.7 ± 1.9 years whilst 12.8 % (n=26) 
had premature menopause, 13.1% (n=31) had early menopause and 5.9% (n=14) had 
late menopause.  
Smoking was the most prevalent risk factor (50.8%, n=134), followed by vitamin D 
deficiency (29.2%, n=77), history of steroid use (21.6%, n=57), and history of 
hyperparathyroidism (15.2%, n=40). Although alcohol consumption was documented 
in 22.0% (n=58), there was no precise quantification of the amount of alcohol 
consumed. HIV infection and celiac disease accounted for the least described risk 
factors (0.4%, n=1 each). None of the male population had a history of rheumatoid 
arthritis.  
Baseline blood tests (Table 2) documented vitamin D deficiency and insufficiency in 
25.8% (n=68) and 26.9% (n=71), respectively, whilst 2.3% (n=6) of patients had 
hyperthyroidism and 10.6% (n=28) had renal failure.  
 
Fragility fracture at presentation/diagnosis 
 
Table 3 and Figure 2 show the history of fragility fractures at presentation. Sustaining 
a fragility fracture was the referring reason in 68.6% (n=181) of patients. Of these, 
91.7% (n=166) were females and 8.3% (n=15) were males. The vertebrae were the 
commonest site of a fragility fracture (54.7%, n=99), followed by hip (14.9%, n=27), 
whilst the wrist represented the least prevalent site (7.2%, n=13). A fracture at both 
the hip and vertebrae was found in 10.5% (n=19) of the patients, denoting that some 
of the vertebral fractures were asymptomatic and only radiologically discovered after 
a hip fracture. Fractures at other sites, like the humerus, ribs, pelvis and ankle 






Vertebral fracture vs nonvertebral fracture 
 
Comparisons between patients who had a vertebral fracture and those who had a 
nonvertebral fracture at diagnosis are shown in Table 4 and Table 5. Age, sex and 
BMI didn’t reveal any significant difference between the two groups (p=0.11, 0.66, 
and 0.25 respectively). Vitamin D deficiency was positively associated with vertebral 
fracture (p=0.003). Height was significantly lower in those patients who had a 
vertebral fracture (p=0.009) and is more likely to be a consequence of the fracture 
than a cause of the fracture as height loss is known to be associated with vertebral 
fractures. (Table 4)  
Baseline blood tests showed that hypercalcemia was more common in patients with a 
vertebral fracture (p<0.05). There were no other significant differences between the 
two groups (Table 5). 
The baseline BMD of patients with a non-vertebral or vertebral fracture is shown in 
Table 6. In comparison to patients with a non-vertebral fracture, patients with a 
vertebral fracture had lower baseline BMD at all sites. The difference was greater at 
the lumbar spine (0.31 g/cm2), but it was not statistically significant. 
 
Fracture vs no fracture 
 
Patients presenting with a fragility fracture were older (67.3±11.6 years) compared to 
those who had no fractures (62.3±13.0 years) (Table 7). The BMI in patients with a 
fragility fracture was 27.3 ± 5 kg/m2, while it was 25.5 ± 5.7 kg/m2 in those without a 
history of fracture. Females accounted for 91.7% (n=166) of patients who had fracture 
and 95.2% (n=79) of patients with no fracture at diagnosis. A history of primary 
hyperparathyroidism, hypogonadism, and vitamin D deficiency was noticed more 
frequently in patients who had no fracture at diagnosis [25.3% (n=21), 21.7% (n=18), 
and 31.3% (n=26) respectively] compared with those who had fractures [10.5% 
(n=19), 6.1% (n=11), and 28.2% (n=51) respectively]. (Table 7) 
Hypercalcemia was more common in patients with no fracture (21.7%, n=18), 
compared with those with a fracture (7.7%, n=14) while hypocalcemia and renal failure 
were more common in patients with a fracture [4.4% (n=8), and 12.7% (n=23), 
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respectively] than those with no fracture [0.0% (n=0), and 6.0%, (5), respectively] 
(Table 8).  
Medications prescribed 
Most of the cohort were on vitamin D (93.2%, n=246) and calcium supplements (86%, 
n=227) at the time of enrolment (Table 9). Bisphosphonates constituted the only 
definitive treatment for osteoporosis with 70.4% (n=186) receiving IV ZA, 9.8% (n=26) 
received alendronate followed by IV ZA, 60.6% (n=160) received IV ZA alone while 
alendronate alone was received by 4.5% (n=12).  
Among those who received IV ZA (n=186), 28.1% (n=45) received 1 dose of IV ZA, 
15.9% (n=42) received 3 doses, and 2.5% (n=4) received a total of 7 doses; the mean 
accumulative dose was 11.6 mg (2.9 doses). 
About 25% (n=66) of the cohort were not yet started on treatment at the time of 
enrolment either because it was their initial visit or their first follow-up visit after 
completion of workup, including DEXA scan. 
Change in BMD on treatment 
Table 10 and Figure 2 show the change in BMD after an average follow-up duration 
of 5.4 ± 0.53 years. The BMD remained stable overall with some improvement in L1-
L4.  Lumbar spine (L1-L4) BMD increased in 73.5% (n=111) of patients, decreased in 
25.8% (n=39) and remained unchanged in 0.7% (n=1); the mean change in lumbar 
spine BMD was 0.033 g/cm2 (4.4%). At the Left femoral neck, 47.7% (n=71) of patients 
had an increase in BMD, 50.3% (n=75) had a decrease in BMD and 2.0% (n=3) 
showed no change in BMD; the mean change in BMD was – 0.003 g/cm2 (- 0.5%). The 
total left hip BMD increased in  54.7% (n=82) of patients, 44.0% (n=66) had a 
decreased BMD, while 1.3% (n=2) had no change in BMD; the mean change in left 
total hip BMD was 0.003 g/cm2 (0.4%). The BMD at the right femoral neck and right 
total hip remained the same with a mean change of 0.001 g/cm2 (0.2%, and 0.1%, 
respectively). Although the DEXA scan was repeated after 3 years of bisphosphonates 
treatment in most patients during follow up, which is the routine practice in the 
Endocrine Clinic at Groote Schuur Hospital, we used the latest DEXA result to see the 




Fracture vs no fracture on treatment  
 
Tables 11, 12, 13 and 14 compare patients who had a fracture and patients who had 
no fracture whilst on treatment with bisphosphonates.  A new fracture was diagnosed 
in 10.6% (n=21) of patients treated with bisphosphonates based on VFA for most of 
the vertebral fractures and clinical presentation with conventional radiography for hip 
and other fractures. Of these, 95.2% (n=20) were females.  Of these fractures whilst 
on treatment 61.9% (n=13) were vertebral, 23.8% (n=5) were hip and 14.3% (n=3) 
were other.  Of note, fracture at diagnosis was reported in 85.7% (n=18) patients with 
fracture on treatment compared to 68.4% (n=121) of patients with no fracture on 
treatment. A history of a vertebral fracture at diagnosis was reported in 71.4% (n=15) 
of patients with a fracture on treatment but in only 48.0% (n=85) of patients with no 
fracture on treatment. 
Of the 139 patients on treatment and who had a fracture at diagnosis, 12.9% (n=18) 
had a refracture during follow up.  
While primary hyperparathyroidism was noted in 16.4% (n=29) of patients who had no 
fracture on treatment, none of the patients who had a fracture on treatment had a 
history of primary hyperparathyroidism. Vitamin D deficiency was present in 24.3% 
(n=43) of patients with no fracture on treatment whilst in 14.3% (n=3) of patients with 
a fracture on treatment. Premature menopause was present in 42.1% (n=8) of women 
who had a fracture on treatment and 8.3% (n=14) of women with no fracture on 
treatment.   A history of smoking was reported in more patients who had a fracture on 
treatment (61.9%, n=13), than who had no fracture (49.2%, n=87). Steroid use was 
described in more patients who had fracture on treatment (33.3%, n=7) than patients 
who had no fracture on treatment (22.6%, n=40). (Table 11) 
Vitamin D deficiency, hypercalcemia, hyperparathyroidism [21.5% (n=38), 11,9% 
(n=21), and 27.7% (n=49), respectively] were more common in patients with no 
fracture on treatment when compared to patients with a fracture on treatment [14.3% 
(n=3), 0.0% (n=0), and 14.3% (n=3), respectively] (Table 12).  Hyperthyroidism was 
present in 4.8% (n=1) of patients with a fracture on treatment and in 4.0% (n=7) of 
patients with no fracture on treatment.  
Multiple doses (3-6) of IV ZA were received by 71.4% (n=15)] of patients with a fracture 





Surprisingly, patients who had a fracture on treatment had a higher mean BMD at all 
sites at baseline and follow-up compared with those who had no fracture on treatment 
(Table 14).  
 
2.5 Discussion 
This is the first audit at Groote Schuur Hospital of patients with osteoporosis attending 
the Endocrine Clinic. This retrospective descriptive study was conducted to highlight 
the clinical presentation, risk factors and treatment outcomes for patients referred to 
the Endocrine Clinic for the management of osteoporosis. Although there is abundant 
descriptive data on osteoporosis worldwide, there remains sparse descriptive data on 
osteoporosis in sub-Saharan Africa and this study will add to the limited literature of 
osteoporosis in this region.  
In our cohort, postmenopausal women aged above 65 years constituted the majority 
of the participants. This was expected as osteoporosis is most prevalent in post-
menopausal women, as they lose the protective effects of estrogen on bone. This 
finding is similar to findings in other studies (1–3).  Surprisingly, in this cohort, the 
males were younger than the females. This is in contrast to most studies that show 
men with osteoporosis to be older than women (4,5).  This data may not be 
representative as osteoporosis remains under diagnosed in men, there were few men 
in this cohort and it is possibly biased as this cohort is in a tertiary centre where only 
the more severe forms of osteoporosis are referred.    
Ethnicity is a well-defined risk factor for osteoporosis and fragility fractures with studies 
showing White and Asian ethnicities to be at higher risk (6–8). Since our study was a 
retrospective review it was not possible to accurately assess ethnicity. However, 
historically, the ethnicity of the majority of patients attending clinics at GSH would be 
from mixed-ancestry or black.  
Most of the patients had a history of an acute fragility fracture at diagnosis and this is 
consistent with studies from developed countries where most cases of osteoporosis 
were diagnosed after a fragility fracture (9,10).  In addition, since GSH is a tertiary 
medical facility, patients are mostly referred once they have sustained a fragility 
fracture.  Vertebral fractures constituted the largest number of fragility fractures in this 
cohort.  Studies from other countries suggest hip fractures are more common (11,12), 




European countries, showing that hip, vertebral, forearm and proximal humerus 
fractures accounted for 49%, 19.6%, 15.5% and 17.9% of fractures, respectively (11). 
A study from the USA in patients admitted with a diagnosis of an osteoporotic fracture 
showed a higher prevalence of hip fractures (50%) compared to vertebral fractures 
(14%) (12).  In addition, a  study from Canada showed that the  site of a fragility fracture 
depended on the sex of the patient with the forearm the dominant site in women and 
the ribs the dominant site in men (5).  There were too few men in this cohort to make 
a meaningful comparison on sex differences in fracture site. The finding of a 
predominance of vertebral fractures in our cohort may be explained by the routine 
screening for vertebral fractures in our institution as part of a DEXA scan. 
Current and previous smoking is a well described risk factor for osteoporosis and 
osteoporotic fractures and was found to be the most common risk factor among the 
study population (13–16).  Excessive alcohol intake is also a well-recognised risk 
factor for osteoporosis, whereas light to moderate alcohol consumption is considered 
beneficial resulting in a higher BMD and reduced age-related bone loss (17–19).  
Alcohol consumption was not common in this cohort and, in the roughly 20% that did 
consume alcohol, there was no clear documentation of the amount of alcohol 
consumed.    
Vitamin D deficiency is prevalent in South Africa. A recent study from KwaZulu-Natal 
revealed that vitamin D deficiency and insufficiency was present in 27% and 38%, 
respectively, in 327 study participants (20). In a study from Cape Town, Charlton et al 
(1996) showed a prevalence of vitamin D deficiency of 17% in 200 coloured 
participants (21).  In this study, 29.2% of our participants were vitamin D deficient.  
Vitamin D has been shown to be more prevalent in patients with osteoporosis, 
although the prevalence does vary. In a study from Colombia, the prevalence of 
vitamin D deficiency was found to be 55.3% in 206 patients diagnosed with 
osteoporosis (22). A significantly higher prevalence of vitamin D deficiency (89%) was 
shown in a study from Germany in 246 patients with a vertebral fragility fracture  (23). 
 
HIV and antiretroviral treatment are associated with an increased risk of osteoporosis. 
In a study from Malawi, 20% of an HIV-infected population was found to have reduced 
BMD (24). In a study from Senegal, the prevalence of osteoporosis in 193 HIV-infected 
patients above 50 years of age was 26% in women and 6% in men (25). In a multi-
national study, including South Africa, the prevalence of osteoporosis in ART-naïve 
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HIV-infected adults with normal and low CD4 cell counts was found to be low (1.9%), 
while 35.1% of the participants were found to have a low BMD (26). Similar findings of 
a low prevalence of low BMD was reported in ART- naïve HIV-infected black South 
African women with low and preserved CD4 counts (27).  A meta-analysis by Brown 
et al (2007) reported a  67% prevalence of low BMD in 884 HIV-infected individuals, 
of whom 15 were osteoporotic (28).   
Antiretroviral therapy, especially efavirenz or lopinavir/ritonavir, was found to be 
associated with a low BMD in a young cohort of HIV-infected South Africans (29). 
Despite South Africa having the highest prevalence of HIV infection worldwide we only 
had one patient with HIV-infection referred to our clinic. This could be explained by 
HIV-infection being more prevalent in young black females who are considered a low 
risk population for osteoporosis. In addition, lack of routine osteoporosis screening 
may be another explanation.  
Bisphosphosphonates (IV zoledronic acid or oral alendronate) were the main definitive 
therapy prescribed for patients in this cohort. About 25% of the cohort had not yet been 
started on treatment (bisphosphosphonates) at the time of enrolment as they were 
either at their initial visit after referral or their first follow-up appointment after 
completion of the osteoporosis workup.  
The recommended dose of zoledronic acid in national and international guidelines is 
5 mg annually (30,31), however, all patients who were treated with zoledronic acid in 
this study received an annual dose of 4 mg. This lower dose of zoledronic acid is a 
decision adopted by our institution on the basis of cost. Other therapeutic agents for 
osteoporosis like denosumab and anabolic agents (teriparatide and abaloparatide) 
were not prescribed to any patient in this cohort as they are not available in our 
institution.  
After a mean duration of 5.2 years, treatment with bisphosphonates increased the 
BMD at the lumbar spine but had no effect at the hips. This is in contrast to other 
studies showing an increase in BMD at all sites after treatment with zoledronic acid. A 
meta-analysis comparing zoledronic acid with placebo showed a difference in BMD in 
favour of zoledronic acid at the lumbar spine of 6.10-6.71%, total hip of 2.10-6.40% 
and femoral neck of 3.30-5.06% after 24 months of treatment (32). Another meta-
analysis revealed an improvement of femoral neck BMD for both zoledronic acid 
(3.20%) and alendronate (3.11%) compared to placebo for average duration of 1.8 




Southern India showed a higher increment in BMD at the lumbar spine (6.1%) while 
the BMD at the femoral neck and total hip remained stable with no statically significant 
increment in patients treated with zoledronic acid (34). A study from China reported a 
5.39% improvement in BMD at the lumbar spine and a 1.9% improvement at the total 
hip in those patients treated with zoledronic acid for two years (35).  
Our study showed an incidence of fracture while on bisphosphonate therapy of 10.6%. 
Of those who had a history of a previous fracture, 12.9% refractured whilst on 
treatment. This is marginally higher than what has been reported in the literature.   
There are no studies from Africa, but in a large study from the USA, the three-year 
subsequent fracture rate was 7.5%  in patients receiving different types of anti-
osteoporotic therapies including oral or injectable bisphosphonates, raloxifene, 
teriparatide, denosumab, and calcitonin (36). Another study from the USA 
demonstrated an 11.3% incidence of subsequent fragility fracture within three years 
(37). A 9.7% refracture rate was demonstrated in a study from 37 fracture clinics in 
Ontario, Canada (38).  
It is surprising that the baseline and follow-up mean BMD at all sites was found to be 
higher in patients who had a fracture on treatment compared to those who had no 
fracture on treatment. Although BMD is known to be a predictor of osteoporotic 
fracture, the high prevalence (85.7%) of a previous fracture in this cohort may explain 
the increased prevalence of fractures whilst on treatment (39,40). This is supported by 
the recommendation for initiation of anti-osteoporotic treatment for postmenopausal 
women with a fragility fracture regardless of the BMD, reflecting the importance of a 
previous fracture as a strong predictor of a subsequent fracture (41). The small 
proportion (10.6%) of patients who had a fracture on treatment might hinder making 
strong comment on this observation.  
The lower improvement of BMD and marginally higher rate of fracture in our study 
compared to previous studies might be explained by the lower dose of zoledronic acid 
we used. Furthermore, genetic factors and different types of bones could also 
contribute. 
This study has several limitations. It is a cross-sectional study so only associations 
can be shown and causation cannot be implied. It contains a biased sample as only 
those with more severe disease or a fragility fracture are referred to a tertiary medical 
centre. Interim exposure to risk factors were not assessed. There was missing blood 




sex comparisons.  
The strengths of this study reside in it being the first description of patients with 
osteoporosis and fractures at Groote Schuur Hospital.  It represents real-world local 
clinical data that can now be used to design long-term prospective studies to better 
guide investigation and management of osteoporosis in our local population.  
Furthermore, it provides some data showing the outcome of using a lower dose of 
zoledronic acid to reduce fractures in people diagnosed with osteoporosis. 
Future studies could include: 
1. Assessing whether men are actually at lower risk for osteoporosis and a fragility 
fracture or whether the low numbers are just a consequence of reduced 
screening for osteoporosis in males as they are deemed to be at lower risk for 
osteoporosis 
2. Prospective study assessing whether the lower dose of ZA used in the public 
sector is effective at reducing recurrent fractures 
 
2.6 Conclusion and Recommendations 
This is the first descriptive study and clinical audit on patients with osteoporosis 
attending the Endocrine Clinic at Groote Schuur Hospital. Although our study 
describes some interesting differences when compared to other studies in the 
literature it does show that our current treatment prevents recurrent fractures in over 
85% of high-risk patients with osteoporosis. The interesting differences highlighted in 
the study deserve further investigation in adequately powered and well-designed 
prospective studies.         
Using the NOFSA guidelines for osteoporosis to screen for high risk groups will help 
in the early initiation of treatment and reducing the number of patients presenting with 
a fragility fracture. Our institution might need to revisit the policy of using the modified 
dose of zoledronic acid (4 mg), as this may be one of the reasons implicated in the 
lower improvement of BMD and marginally higher rate of fractures on treatment in our 
patients compared with studies using the recommended 5 mg dose.  However, this 
would have to be balanced with cost and a prospective study would be needed to 
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Table 1: Baseline Characteristics and pre-existing risk factors for the 
whole population, females and males 
TABLES 
Total Female Male 
N=264 N=245 (92.8% N=19 (7.2%) 
Age 65.7 (12.3) 66.2 (11.9) 60.1 (15.9) 
BMI 26.7 (5.5) 26.6 (5.4) 27.1 (6.9) 
Menarche 13.7 (1.9) 13.7 (1.9) 
Menopausal 237 (96.7%) 
 Premature 26 (11.0%) 26 (11.0%) 
 Early 31 (13.1%) 31 (13.1%) 
 Normal 129 (54.4%) 137 (57.8%) 
 Late 14 (5.9%) 6 (2.5%) 
 Uncertain 37 (15.6%) 37 (15.6%) 
Smoking 134 (50.8%) 121 (49.4%) 13 (68.4%) 
Alcohol 58 (22.0%) 54 (22.0%) 4 (21.1%) 
HIV-infected 1 (0.4%) 1 (0.4%) 0 (0.0%) 
Vitamin D deficiency 77 (29.2%) 68 (27.8%) 9 (47.4%) 
Hyperparathyroidism 40 (15.2%) 38 (15.5%) 2 (10.5%) 
Hyperthyroidism 5 (1.9%) 4 (1.6%) 1 (5.3%) 
IBD 11 (4.2%) 8 (3.3%) 3 (15.8%) 
Rheumatoid arthritis 14 (5.3%) 14 (5.7%) 0 (0.0%) 
Hypogonadism 29 (11.0%) 26 (10.6%) 3 (15.8%) 
Coeliac Disease 1 (0.4%) 1 (0.4%) 0 (0.0%) 
Family hx Osteoporosis 73 (27.8%) 67 (27.5%) 6 (31.6%) 
Family hx Fragility 
fracture 
47 (17.8%) 44 (18.0%) 3 (15.8%) 




Table 2: Baseline blood test results for the whole population, females 
and males  
 
    
  
 Total Female Male 
 n=264 n=245 n=19 
Fracture at 
diagnosis/presentation 
181 (68.6%) 166 (67.8%) 15 (78.9%) 
Vitamin D deficiency 68 (25.8%) 59 (24.1%) 9 (47.4%) 
Vitamin D insufficiency 71 (26.9%) 67 (27.3%) 4 (21.1%) 
Hypercalcaemia 32 (12.1%) 30 (12.2%) 2 (10.5%) 
Hypocalcaemia 8 (3.0%) 8 (3.3%) 0 (0.0%) 
Hyperphosphataemia 5 (1.9%) 5 (2.0%) 0 (0.0%) 
Hypophosphataemia 5 (1.9%) 4 (1.6%) 1 (5.3%) 
Hyperparathyroidism# 76 (28.8%) 71 (29.0%) 5 (26.3%) 
Paraproteinaemia$ 4 (1.5%) 4 (1.6%) 0 (0.0%) 
Hypothyroidism* 14 (5.3%) 12 (4.9%) 2 (10.5%) 
Hyperthyroidism* 6 (2.3%) 5 (2.0%) 1 (5.3%) 



















# n=205, 191 females, 14 males; $n=161, 151 females, 10 males;  




Table 3: Fracture History among the Study population 
 
 
   Total Female Male 
  N=264 N=245 N=19 
Age  65.7 (12.3) 66.2 (11.9) 60.1 (15.9) 
Menopause Premature 26 (11.0%) 26 (11.0%)  
 Early 31 (13.1%) 31 (13.1%)  
 Normal 129 (54.4%) 137 (57.8%)  
 Late 14 (5.9%) 6 (2.5%)  
 Uncertain 37 (15.6%) 37 (15.6%)  
BMI  26.7 (5.5) 26.6 (5.4) 27.1 (6.9) 
Height  155.4 (8.2) 154.7 (7.2) 165.1 (14.3) 
Weight  64.3 (14.1) 63.7 (13.4) 73.7 (20.6) 
Fracture at 
diagnosis/presentation 
 181 (68.6%) 166 (67.8%) 15 (78.9%) 
Fracture Site Category No Fracture 83 (31.4%) 79 (32.2%) 4 (21.1%) 
 Non-Vertebral 63 (23.9%) 57 (23.3%) 6 (31.6%) 





















Table 4: Baseline characteristics and pre-existing risk factors of 
patients with a non-vertebral or vertebral fracture 
 
 
 Non-Vertebral Vertebral p-value 
 n=63 n=118  
Age 69.2 (12.0) 66.3 (11.3) 0.11 
Female sex 57 (90.5%) 109 (92.4%) 0.66 
Weight 65.3 (14.7) 66.0 (15.0) 0.79 
Height 158.0 (6.6) 154.1 (9.3) 0.009 
BMI 26.5 (5.7) 27.6 (5.7) 0.25 
Vitamin D deficiency 24 (38.1%) 27 (22.9%) 0.030 
Hyperparathyroidism 6 (9.5%) 13 (11.0%) 0.75 
CKD 12 (19.0%) 18 (15.3%) 0.51 
Diabetes 9 (14.3%) 19 (16.1%) 0.75 
IBD 1 (1.6%) 1 (0.8%) 0.65 
Rheumatoid arthritis 3 (4.8%) 9 (7.6%) 0.46 
Hyperthyroidism 1 (1.6%) 3 (2.5%) 0.68 
Hypogonadism 3 (4.8%) 8 (6.8%) 0.59 
Steroid Use 14 (22.2%) 28 (23.7%) 0.82 
Smoking 30 (47.6%) 64 (54.2%) 0.40 
Alcohol ever 10 (15.9%) 33 (28.0%) 0.069 
Menarche (years) 13.6 (2.1) 13.5 (1.8) 0.82 
Menopause 57 (100%) 106 (97.2%) 0.37 
Early 3 (5.3%) 11  
Late 11 (14.3%) 12  
Normal 30 (52.6%) 58  
Premature 5 (8.8%) 7  
Uncertain 8 (14.0%) 18  
Family Hx osteoporosis 20 (31.7%) 30 (25.4%) 0.36 









Vitamin D deficiency 20 (31.7%) 25 (21.2%) 0.28 
Vitamin D insufficiency 17 (27.0%) 34 (28.8%) 
Hypercalcaemia 4 (6.3%) 10 (8.5%) 0.048 
Hypocalcaemia 6 (9.5%) 2 (1.7%) 
Hyperphosphataemia 3 (4.8%) 2 (1.7%) 0.098 
Hypophosphataemia 0 (0.0%) 2 (1.7%) 
Hyperparathyroidism # 16 (25.4%) 32 (27.1%) 0.97 
Hypothyroidism$ 4 (6.3%) 5 (4.2%) 0.89 
Hyperthyroidism$  1 (1.6%)  3 (2.5%) 
Renal failure  9 (14.3%) 14 (11.9%) 0.69 
# n=144, 50 non-vertebral fractures, 94 vertebral fractures; $n=168, 59 non-




Table 6: Baseline BMD of patients with a non-vertebral or vertebral fracture               
 
 Non-Vertebral Vertebral p-value 
 N=63 N=118  
L1-L4_BMD 0.777 (0.149) 0.746 (0.150)  0.20 
left femoral neck_BMD 0.591 (0.123) 0.575 (0.104)  0.41 
left total hip_BMD 0.714 (0.130) 0.708 (0.133)  0.80 
right total hip_BMD 0.713 (0.122) 0.698 (0.135)  0.53 























Table 7: Baseline characteristics and pre-existing risk factors of 




 No Fracture Fracture 
 N=83 N=181 
Age 62.3 (13.0) 67.3 (11.6) 
Female sex 79 (95.2%) 166 (91.7%) 
BMI 25.5 (5.0) 27.3 (5.7) 
Height 155.5 (7.2) 155.3 (8.7) 
Weight 61.3 (12.2) 65.8 (14.9) 
Menarche (years) 14.0 (1.7) 13.5 (1.9) 
Menopause 74 (93.7%) 163 (98.2%) 
Premature 12 (16.2%) 14 (8.6%) 
Early 8 (10.8%) 23 (14.1%) 
Normal 41 (55.4) 88 (54.0%) 
Late 2 (2.7%) 12 (7.4%) 
Uncertain 11 (14.9%) 26 (15.9%) 
Smoking 40 (48.2%) 94 (51.9%) 
Alcohol  15 (18.1%) 43 (23.8%) 
Vitamin D deficiency 26 (31.3%) 51 (28.2%) 
Hyperparathyroidism 21 (25.3%) 19 (10.5%) 
Hyperthyroidism 1 (1.2%) 4 (2.2%) 
Hypogonadism 18 (21.7%) 11 (6.1%) 
IBD 9 (10.8%) 2 (1.1%) 
Rheumatoid arthritis 2 (2.4%) 12 (6.6%) 
Coeliac Disease 0 (0.0%) 1 (0.6%) 
Family Hx Osteoporosis 23 (28.0%) 50 (27.6%) 
Family Hx of fragility 
fracture 
13 (15.7%) 34 (18.8%) 








Table 8: Baseline blood test results of patients with 
no fracture or with a fracture 
No Fracture Fracture 
N=83 N=181 
Vitamin D deficiency 23 (27.7%) 45 (24.9%) 
Vitamin D 
insufficiency 
20 (24.1%) 51 (28.2%) 
Hypercalcaemia 18 (21.7%) 14 (7.7%) 
Hypocalcaemia 0 (0.0%) 8 (4.4%) 
Hyperphosphataemia 0 (0.0%) 5 (2.8%) 
Hypophosphataemia 3 (3.6%) 2 (1.1%) 
Hyperparathyroidism# 28 (33.7%) 48 (26.5%) 
Paraproteinemia* 1 (1.2%) 3 (1.7%) 
Hypothyroidism$ 5 (6.0%) 9 (5.0%) 
Hyperthyroidism$ 2 (2.4%) 4 (2.2%) 
Renal failure 5 (6.0%) 23 (12.7%) 
# n=205, 61 no fracture, 144 fracture; *n=161, 43 no fracture, 
118 fracture; $n=248, 80 no fracture, 168 fracture 
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Table 9: Distribution of medication use among study population 
Medications Count (n) Percentage 
Calcium 227 86% 
Vitamin D 246 93.2% 
Bisphosphonates 198 75% 
Alendronate 12 6.1% 
Alendronate 
followed by IV ZA 
26 13.1% 
IV ZA 160 80.8% 






















* Dose = 4 mg (corrected to eGFR)
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Table 8: Bone mineral density (BMD) (g/cm2) at diagnosis and at current DEXA 
scan
















0,594 0,591 - 0,003 (-0.5%) 71 (47.7%) 75 (50.3%) 3 (2.0%) 




0,591 0,592 0,001 (0.2%) 72 (48.6%) 76 (51.4%) 0 (0.0%) 
total hip 0,720 0,721 0,001 (0.1%) 77 (51.7%) 69 (46.3%) 3 (2.0%) 
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# Refracture rate (18/139) = 12.9%  
Table 11: Baseline characteristics and pre-existing risk 




No Fracture Fracture 
N=177 (89.4%) N=21 (10.6%) 
Age 65.4 (10.8) 65.7 (14.0) 
Female sex 171 (96.6%) 20 (95.2%) 
Vitamin D deficiency 43 (24.3%) 3 (14.3%) 
CKD 22 (12.4%) 2 (9.5%) 
Diabetes 23 (13.0%) 4 (19.0%) 
Fracture at diagnosis 121 (68.4%) #18 (85.7%) 
Fracture Site 
Non-Vertebral 36 (20.3%) 3 (14.3%) 
Vertebral 85 (48.0%) 15 (71.4%) 
IBD 8 (4.5%) 1 (4.8%) 
RA 13 (7.3%) 1 (4.8%) 
Hyperthyroidism 2 (1.1%) 1 (4.8%) 
Hypogonadism 16 (9.0%) 3 (14.3%) 
Steroid Use 40 (22.6%) 7 (33.3%) 
HIV-infection 0 (0.0%) 1 (4.8%) 
Coeliac Disease 1 (0.6%) 0 (0.0%) 
Smoking 90 (50.8%) 8 (38.1%) 
Alcohol ever 35 (19.8%) 8 (38.1%) 
Menarche (years) 13.6 (1.9) 14.2 (2.1) 
Menopause 168 (98.2%) 19 (95.0%) 
Premature 14 (8.3%) 8 (42.1%) 
Early 25 (14.9%) 2 (10.5%) 
Normal 92 (54.8%) 7 (36.9%) 
Late 9 (5.3%) 0 (0.0%) 
Uncertain 28 (16.7%) 2 (10.5%) 
Family Hx 
Osteoporosis 
54 (30.7%) 4 (19.0%) 
Family History fracture 34 (19.3%) 3 (14.3%) 
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Table 12: Baseline blood test results of patients with 
no fracture or with a fracture whilst on treatment 
No Fracture Fracture 
N=177 N=21 
Vitamin D deficiency 38 (21.5%) 3 (14.3%) 
Vitamin D 
insufficiency 
41 (23.2%) 6 (28.6%) 
Hypercalcaemia 21 (11.9%) 0 (0.0%) 
Hypocalcaemia 2 (1.1%) 1 (4.8%) 
Hyperphosphataemia 2 (1.1%) 0 (0.0%) 
Hypophosphataemia 3 (1.7%) 0 (0.0%) 
Hyperparathyroidism 
#
49 (27.7%) 3 (14.3%) 
Paraproteinemia* 4 (2.3%) 0 (0.0%) 
Hypothyroidism$ 7 (4.0%) 3 (14.3%) 
Hyperthyroidism$ 3 (1.7%) 1 (4.8%) 
Renal failure 17 (9.6%) 2 (9.5%) 
# n=151, 137 no fracture, 14 fracture; *n=112, 103 no fracture, 9 
fracture; $n=182, 161 no fracture, 21 fracture 
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Table 13: Treatment of patients with no fracture or with a fracture 
whilst on treatment 
IV Zoledronic Acid No Fracture Fracture 
N=177 N=21 
Number IV ZA Doses 
0 11 (6.2%) 1 (4.8%) 
1 45 (25.4%) 0 (0.0%) 
2 35 (19.8%) 5 (23.8%) 
3 37 (20.9%) 5 (23.8%) 
4 16 (9.0%) 1 (4.8%) 
5 21 (11.9%) 7 (33.3%) 
6 8 (4.5%) 2 (9.5%) 
7 4 (2.3%) 0 (0.0%) 
Oral Bisphosphonates 34 (19.2%) 4 (19.0%) 
Calcium Supplementation 161 (91.0%) 19 (90.5%) 
Vitamin D 
Supplementation 
173 (97.7%) 20 (95.2%) 
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Table 14: Bone mineral density (BMD) (g/cm2) at diagnosis and 
at current DEXA scan patients with no fracture or with a fracture 
whilst on treatment 
BMD No Fracture Fracture 
At Diagnosis 
L1-L4 0.747 (0.127) 0.770 (0.087) 
left total hip 0.713 (0.119) 0.732 (0.125) 
left femoral neck 0.587 (0.101) 0.602 (0.130) 
right total hip 0.705 (0.129) 0.763 (0.110) 
right femoral neck 0.579 (0.118) 0.621 (0.104) 
Current 
L1-L4 0.783 (0.125) 0.872 (0.109) 
left total hip 0.720 (0.115) 0.752 (0.105) 
left femoral neck 0.588 (0.099) 0.613 (0.107) 
right total hip 0.712 (0.123) 0.771 (0.117) 
right femoral neck 0.587 (0.105) 0.620 (0.124) 
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Figure 1: Study population selection and exclusion criteria 
FIGURES 
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Figure 2: Distribution of fracture sites at diagnosis    
Vertebrae only; 
54,7%, n=99
Hip only; 14,9%, 
n=27
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